alexa Inhibition Of HDAC6 As Targeted Therapy For Breast Cancers
ISSN: 1948-5956

Journal of Cancer Science & Therapy
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

10th International Conference on CANCER STEM CELLS AND ONCOLOGY RESEARCH
June 26-28, 2017 London, UK

Jose Silva
Mount Sinai School of Medicine, USA
Posters & Accepted Abstracts: J Cancer Sci Ther
DOI: 10.4172/1948-5956-C1-103
Abstract
Due to their unique biology, the homeostasis of cancer cells presents different requirements from non-transformed cells. Targeted therapies that interfere with these requirements have been successfully used as highly selective and low toxic anticancer strategies. Recently, we have identified and validated that viability of inflammatory breast cancers (IBC) depends on histone deacetylase 6 (HDAC6) function ( Putcha et al. Breast Cancer Res.). Thus, HDAC6 inhibitors, which are currently being tested in advanced clinical trials for other tumor types, represent a novel targeted therapeutic option for these patients. We reasoned that additional breast cancers, other than IBCs, may present the same dependency and that identification of patient populations that can benefit from HDAC6 targeted therapy would be necessary in order to rapidly transition this finding into the clinic. By using system biology strategies to interrogate the regulatory circuit of breast cancer cells we have found that HDAC6 activity is highly increased in HDAC6-dependent cells, acting as a master regulator. We have also developed an algorithm (HDAC6-score) based on mRNA expression profiling to evaluate the HDAC6 activity of individual tumor samples. Thus, the HDAC6-score works as a biomarker to easily identify cancers with high HDAC6 activity that are likely to depend on HDAC6 function. Using our HDAC6-score algorithm we have analyzed ~3,000 primary breast cancers. Interestingly, we have found that a group of ~20% of breast cancers that is enriched in hormone receptor positive (HR+) and HER2 positive (HER+) tumors presents an HDAC6-score predictive of good response to HDAC6 inhibitors. To validate our findings, we correlate the HDAC6-score and the growth inhibitory response to the leading HDAC6 inhibitor, Ricolinostat, in preclinical breast cancer models in vitro and in vivo. Our preclinical studies confirmed the high levels of HDAC6 activity in HR+ and HER2+ breast cancer cells as well as their sensitivity to HDAC6 inhibition. Clinical considerations: Despite the success of Pan-histone deacetylase inhibitors (HDACis) against cutaneous T-cell lymphoma, these inhibitors suffer from ineffectively low concentrations in solid tumors and cardiac toxicity due to its activity against HDAC1, HDAC2 and HDAC3, hindering their progress in the clinic. More-selective HDAC inhibitors represent a novel and promising class of anticancer drugs with wider therapeutic indexes. The leading HDAC6 inhibitor Ricolinostat, which is in Phase II trials for multiple myeloma and lymphoma, has a 20-fold more potency for HDAC6 inhibition than other class-I/II histone deacetylases. Thus, Ricolinostat can be dosed more frequently with better tolerability than non-selective FDA-approved HDACis.
Biography

Email: [email protected]

image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords